Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $118.7152W HIGH $260.19
Volume
1.07 M
Value Traded
306.15 M
Short % Float
7.11%
-5.12%Week
-19.25%1 Month
-27.25%3 Month
-4.51%6 Month
+320.77%5 Year
+2,521.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.91 B
EPS (TTM)
-3.66
P/E Ratio
-
Ent. Value
8.78 B
Total Shares
52.38 M
Float Shares
44.18 M
Insiders
15.65%
Institutions
73.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AXSM Catalyst Timeline
Dated clinical, regulatory and corporate events for Axsome Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Axsome Therapeutics, Inc.
879Total events
6Upcoming
227Tier-1 (high impact)
2015 to 2040Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationPresentation
Shared Goals survey results presented at Psych Congress 2026
agitation associated with dementia due to Alzheimer's diseasesource ↗
●Poster PresentationDextromethorphan-BupropionPresentation
Poster 102: Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants with Major Depressive Disorder and Anxious Distress
Major depressive disorder with anxious distresssource ↗
●Poster PresentationSolriamfetolApprovedPresentation
Poster 156: Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials
Excessive daytime sleepiness in narcolepsy and obstructive sleep apneasource ↗
●Poster PresentationAXS-12FiledPresentation
Poster 154: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
Narcolepsy with cataplexysource ↗
▲First Patient DosedAXS-05ApprovedTrial
First patient dosed in SUMMIT Phase 3 trial of AXS-05 for smoking cessation
smoking cessationsource ↗
▲FDA Filing AcceptedAXS-12FiledRegulatory Filing
NDA submission for AXS-12 accepted by FDA
cataplexy in narcolepsysource ↗
▲FDA Filing AcceptedAXS-12FiledRegulatory Filing
FDA accepts NDA for AXS-12 for cataplexy in narcolepsy
cataplexy in narcolepsysource ↗
▲AdCom CancelledAXS-12FiledAdvisory Committee
FDA does not plan to hold advisory committee meeting
cataplexy in narcolepsysource ↗
▲First Patient DosedSolriamfetolApprovedTrial
First patient dosed in FOCUS-2 Phase 3 trial of solriamfetol in children with ADHD
attention deficit hyperactivity disorder (ADHD)source ↗
▲Trial InitiationSolriamfetolApprovedTrial
FOCUS-2 Phase 3 trial initiated
ADHD in children and adolescentssource ↗
◆Trial InitiationAXS-05ApprovedTrial
Pivotal Phase 2/3 trial of AXS-05 in smoking cessation to be initiated
smoking cessationsource ↗
▲First Patient DosedSolriamfetolApprovedTrial
First patient dosed in FOCUS-3 Phase 3 trial of solriamfetol in adolescents with ADHD
attention deficit hyperactivity disorder (ADHD)source ↗
◆Poster PresentationAXS-12FiledPresentation
Symptom Burden and Quality of Life in Patients with Narcolepsy Who Experience Residual Cataplexy: Subgroup Analysis from the CRESCENDO Survey
Narcolepsy with Cataplexysource ↗
◆Poster PresentationAXS-12FiledPresentation
Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
Narcolepsy with Cataplexysource ↗
◆Poster PresentationSolriamfetolApprovedPresentation
Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials
Excessive Daytime Sleepiness in Narcolepsy and OSAsource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationSYMBRAVOApprovedPresentation
SYMBRAVO sustained pain relief and pain freedom among 2-hour responders in Phase 3 MOMENTUM and MOVEMENT trials
Migrainesource ↗
▲Hatch Waxman LitigationSolriamfetolApprovedIP / Competition
Settlement resolving all SUNOSI patent litigation
excessive daytime sleepiness associated with narcolepsy and obstructive sleep apneasource ↗
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference Fireside Chat
▲Product LaunchAUVELITYApprovedPost-Market
AUVELITY launched for Alzheimer's disease agitation
agitation associated with dementia due to Alzheimer's diseasesource ↗
▲Trial InitiationSolriamfetolApprovedTrial
FOCUS-3 Phase 3 trial initiated
ADHD in children and adolescentssource ↗
◆Poster PresentationAUVELITYApprovedPresentation
Poster presentation: Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg/105 mg)
Major Depressive Disordersource ↗
◆Poster PresentationSolriamfetolApprovedPresentation
Poster presentation: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study
Obstructive Sleep Apneasource ↗
◆Poster PresentationAUVELITYApprovedPresentation
Poster presentation: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious Distress
Major Depressive Disorder with Anxious Distresssource ↗
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
◆Quarterly UpdateCorporate
Axsome to report Q1 2026 financial results and host conference call
●NDA SubmissionAXS-12FiledRegulatory Filing
NDA submission for AXS-12 for cataplexy in narcolepsy
cataplexy in narcolepsysource ↗
▲FDA ApprovalAUVELITYApprovedFDA Decision
FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease
agitation associated with dementia due to Alzheimer's diseasesource ↗
●Oral PresentationAUVELITYApprovedPresentation
Virtual investor event and conference call discussing FDA approval of AUVELITY
agitation associated with dementia due to Alzheimer's diseasesource ↗
◆FDA Filing AcceptedAXS-05ApprovedRegulatory Filing
sNDA for AXS-05 for Alzheimer's disease agitation granted Priority Review
Alzheimer's disease agitationsource ↗
◆PDUFA DateAXS-05ApprovedRegulatory Filing
PDUFA target action date set for AXS-05 sNDA
Alzheimer's disease agitationsource ↗
▲Product LaunchAUVELITYApprovedPost-Market
Launch of AUVELITY for agitation associated with dementia due to Alzheimer's disease with patient support programs
Agitation Associated with Dementia due to Alzheimer's Diseasesource ↗
▲Partnership / LicensebalipodectCorporate
Axsome acquires exclusive global rights to balipodect from Takeda
schizophrenia, Tourette syndromesource ↗
▲FDA ApprovalAUVELITYApprovedFDA Decision
FDA approval of AUVELITY for Alzheimer's disease agitation
agitation associated with dementia due to Alzheimer's diseasesource ↗
◆Trial InitiationAXS-05ApprovedTrial
Initiation of pivotal Phase 2/3 trial of AXS-05 in smoking cessation
smoking cessationsource ↗
◆Trial InitiationSolriamfetolApprovedTrial
Initiation of pediatric Phase 3 trial of solriamfetol in adolescents with ADHD
ADHD in adolescentssource ↗
▲Partnership / LicenseAXS-20Corporate
Acquisition of balipodect (AXS-20) for schizophrenia and Tourette syndrome
schizophrenia and Tourette syndromesource ↗
◆Oral PresentationPresentation
Axsome to present at TD Cowen, Leerink, and Citizens conferences in March 2026
◆Oral PresentationPresentation
Presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲First Patient DosedSolriamfetolApprovedTrial
First patient dosed in CLARITY Phase 3 trial of solriamfetol for MDD with EDS
major depressive disorder with excessive daytime sleepinesssource ↗
▲Partnership / LicenseAXS-17Corporate
Acquired AXS-17, a novel oral GABAAα2,3 receptor PAM
epilepsysource ↗
▲Hatch Waxman LitigationSolriamfetolApprovedIP / Competition
Settlement of patent litigation with Alkem Laboratories Ltd. for SUNOSI
excessive daytime sleepiness associated with narcolepsy and obstructive sleep apneasource ↗
●Trial InitiationSolriamfetolApprovedTrial
Initiation of CLARITY Phase 3 trial of solriamfetol in MDD with EDS
major depressive disorder with excessive daytime sleepinesssource ↗
Past FDA Catalysts and PDUFA Decisions
How AXSM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-18 | AXS-12 | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B62 / 100
Pipeline Score
$2.0B
Pipeline Value
$3.4B
Commercial Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 5%
Small Cap(rank 34 of 658)
Percentile Rank
Axsome Therapeutics, Inc. holds a solid B-grade pipeline (62/100), with $3.0B risk-adjusted pipeline value, led by Solriamfetol in ADHD (Phase 3), across $82B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $776.6M x 4.4 = $3.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Auvelity | $624M | $389M | +60.5% |
| Sunosi | $134M | $101M | +32% |
| Symbravo | $13M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Solriamfetol Small moleculeNCT07484217 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Phase 3 | RECRUITING | 508 | Dec 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AXSM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Dextromethorphan-Bupropion Breakthrough | Major Depressive Disorder | 2026-09-17 | Anti-Anhedonic Effects of Dextromethorphan-Bupropion Mediate Improvements in Functioning and Quality of Life in Major Depressive DisorderRead More | Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jacobson Mark L.Officer (Chief Operating Officer) | Option | 10,000 10,000 held | $12.95 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AXSM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.5 % (-16.7 %) | 171.34 M | 700.00 K | -36.36% ( -400.00 K) |
AXSM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AXSM ranks across every disease it competes in
Competitive Position is a premium feature
See how AXSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAXSM News
AXSM▼ -1.7%today
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Axsome Therapeutics will report its third quarter 2026 financial results on November 2, 2026. A conference call will follow at 8:00 a.m. ET to discuss these results and provide a business update. The company focuses on innovative treatments for CNS disorders and has several FDA-approved products.
Read more →AXSMAxsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
Axsome Therapeutics presented results from the Shared Goals survey at Psych Congress 2026, highlighting the significant impact of agitation in Alzheimer's disease on patients and caregivers. The survey revealed that 97% of caregivers noted a negative effect on their loved ones' quality of life, with many wishing they had recognized symptoms earlier. Caregivers expressed a desire for better resources and support in managing agitation symptoms.
Read more →AXSMAxsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics presented ten posters at Psych Congress 2026, highlighting new data on major depressive disorder and Alzheimer's disease agitation. The presentations included real-world treatment patterns and clinical outcomes, showcasing the company's advancements in CNS disorder treatments. This event underscores Axsome's commitment to addressing critical gaps in psychiatric and neurological care.
Read more →AXSMAxsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics, a biopharmaceutical leader in CNS disorders, will participate in several investor conferences in September 2026. These events include fireside chats at notable healthcare conferences in Boston and New York, showcasing the company's commitment to investor engagement. Live webcasts will be available for select sessions, enhancing accessibility for stakeholders.
Read more →AXSMAxsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Axsome Therapeutics has initiated the SUMMIT Phase 3 trial for AXS-05, targeting smoking cessation. This trial will evaluate the efficacy and safety of AXS-05 compared to bupropion and placebo over a 12-week period. Smoking cessation remains a critical health issue, with millions of adults seeking effective treatments.
Read more →AXSMAxsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics reported a strong financial performance for Q2 2026, with total net product revenue reaching $218.4 million, a 46% increase year-over-year. The company highlighted robust sales growth for AUVELITY and SUNOSI, alongside the successful launch of AUVELITY for Alzheimer's agitation. Additionally, Axsome initiated Phase 3 trials for solriamfetol in ADHD and received FDA acceptance for its NDA submission for AXS-12 targeting narcolepsy. Despite a net loss of $51.3 million, the company remains optimistic about its commercial prospects.
Read more →AXSMAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics announced the FDA's acceptance of its New Drug Application for AXS-12, aimed at treating cataplexy in narcolepsy. The FDA has set a target action date of May 1, 2027, and does not plan to hold an advisory committee meeting regarding the application. AXS-12 is a norepinephrine reuptake inhibitor designed to help maintain muscle tone during wakefulness.
Read more →AXSMAxsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
Axsome Therapeutics will announce its second quarter 2026 financial results on August 10, 2026, prior to the U.S. market opening. Following the report, management will host a conference call to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 30 days.
Read more →AXSMAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics has commenced the FOCUS-2 Phase 3 trial for solriamfetol, targeting children aged 6 to under 12 with ADHD. This trial follows the FOCUS-3 trial for adolescents and aims to evaluate the drug's efficacy and safety. Approximately 468 children will participate, with results expected to contribute to ADHD treatment advancements.
Read more →AXSMAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics has commenced the FOCUS-3 Phase 3 trial for solriamfetol, targeting adolescents aged 12 to under 18 with ADHD. This randomized, double-blind study will evaluate the drug's efficacy and safety over six weeks, with 468 participants receiving either solriamfetol or a placebo. The primary measure will be the change in ADHD symptoms as assessed by the ADHD Rating Scale.
Read more →AXSMAxsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics is emphasizing the importance of brain health during Alzheimer's & Brain Awareness Month. The company is collaborating with patients, caregivers, and advocacy organizations to promote awareness and provide resources. They will participate in over 30 events aimed at ending Alzheimer's and will illuminate their headquarters in purple to support the cause.
Read more →AXSMAxsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics presented new data on its sleep medicine portfolio at SLEEP 2026, highlighting AXS-12 and solriamfetol. The presentations included findings from Phase 3 trials and analyses related to narcolepsy and excessive daytime sleepiness. The event showcased the company's commitment to advancing treatments for central nervous system disorders.
Read more →AXSMAxsome Therapeutics Presents New SYMBRAVO Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Axsome Therapeutics announced the presentation of new data on SYMBRAVO at the American Headache Society's 68th Annual Scientific Meeting. The presentations, occurring between June 4-7 in Orlando, cover various analyses related to the acute treatment of migraines using SYMBRAVO. Notable authors from respected institutions will lead these discussions, which focus on efficacy and comparisons to other migraine treatments. This meeting represents a significant exposure for Axsome's migraine therapy.
Read more →AXSM▲ +5.1%on this newsshared move
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Axsome Therapeutics has successfully settled all patent litigation concerning its product SUNOSI (solriamfetol). The settlement permits five companies to sell generic versions of SUNOSI starting in 2040, subject to FDA approval. This resolution eliminates any remaining patent disputes related to SUNOSI, allowing Axsome to focus on its broader business objectives.
Read more →AXSMAxsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics is enhancing its commitment to the migraine community by supporting educational initiatives during Migraine and Headache Awareness Month. The company is backing the Headache in the City campaign and illuminating its headquarters in purple to raise awareness. This effort aims to reduce stigma and improve understanding of migraine's impact on millions.
Read more →AXSMAxsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
Axsome Therapeutics has announced new data presentations on AUVELITY® for major depressive disorder at the ASCP 2026 Annual Meeting. The presentations will cover various aspects of the treatment, including its effects and real-world clinical outcomes. The event is set to take place from May 26-29 in Miami, FL, showcasing advancements in CNS disorder treatments.
Read more →AXSMAxsome Therapeutics Recognizes Mental Health Month
Axsome Therapeutics is recognizing Mental Health Month by supporting initiatives aimed at improving mental health awareness and providing resources for individuals affected by mental health conditions. The company emphasizes the importance of community support and highlights various organizations that offer educational tools and assistance. This year's theme, 'More Good Days, Together,' focuses on fostering hope and recovery for those impacted by mental illness.
Read more →AXSM▲ +8.3%on this newsshared move
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics reported a strong financial performance for Q1 2026, with total net product revenue reaching $191.2 million, a 57% increase from the previous year. The company highlighted the FDA approval of AUVELITY for treating agitation associated with Alzheimer's disease and the expansion of its product pipeline. Despite these successes, Axsome recorded a net loss of $64.5 million due to rising operational costs.
Read more →About Axsome Therapeutics, Inc.
HeadquartersONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next AXSM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime